| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | STX-1150 elevated low-density lipoprotein cholesterol (LDL-C), increased risk of atherosclerotic cardiovascular disease (ASCVD) | Phase 1 | — | Subscribe to access the data. | CRISPR-Based Gene Editing Therapies | Cardiovascular System | |
Phase 1 data readout example | STX-1150 elevated low-density lipoprotein cholesterol (LDL-C), increased risk of atherosclerotic cardiovascular disease (ASCVD) | Phase 1 | — | Subscribe to access the data. | CRISPR-Based Gene Editing Therapies | Cardiovascular System | |
Phase 1 data readout example | STX-1150 elevated low-density lipoprotein cholesterol (LDL-C), increased risk of atherosclerotic cardiovascular disease (ASCVD) | Phase 1 | — | Subscribe to access the data. | CRISPR-Based Gene Editing Therapies | Cardiovascular System |
Recent Updates
Recently added Catalysts
Scribe Therapeutics Inc. Common Stock
$26.62
-1.46 (-5.18%)
Market Cap
503.87 M
EPS
-
P/E Ratio
-
Value Trade
3.69 M
-9.5 %
Week
-29.3 %
1 Month
21.64 %
3 Month
21.64 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
285.88 K
52 Week Range
-
% held by Insiders
36.14 %
% held by Institutions
25.84 %
Enterprise Value
463.98 M
Total Shares
18.93 M
Short %
6.44 %
Float Shares
12.09 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Scribe Therapeutics Inc. Common Stock
12Total events
3Upcoming
1Tier-1 (high impact)
2026 – 2029Coverage
Upcoming catalysts 2
TBD
T2Oral Presentation
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SCTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SCTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-SCTX
Sep 2, 2026Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Scribe Therapeutics reported its Q2 2026 financial results, highlighting the initiation of a Phase 1 trial for STX-1150, a novel LDL-C lowering therapy. The company secured over $25 million in grants from CIRM and raised approximately $155.5 million through an IPO. Despite a net loss of $6.5 million, Scribe is well-funded into 2029 and is advancing its cardiometabolic pipeline.
Read more →-SCTX
Sep 1, 2026▼ -5%on this newsshared move
Scribe Therapeutics to Participate in Upcoming Investor Conferences
Scribe Therapeutics Inc. will participate in several upcoming investor conferences, showcasing its innovative CRISPR technologies aimed at disease prevention and therapeutic intervention. CEO Benjamin Oakes will engage in discussions at the Wells Fargo Healthcare Conference and the H.C. Wainwright Global Investment Conference, while CFO David Parrot will present at the Cell & Gene Meeting on the Mesa. The company aims to improve cardiovascular health through its lead candidate, STX-1150.
Read more →-SCTX
Jul 27, 2026Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
Scribe Therapeutics has successfully closed its initial public offering, raising approximately $155.51 million. The offering included the full exercise of underwriters' option to purchase additional shares, totaling 9,867,000 shares sold at $15.00 each. Additionally, Scribe closed a concurrent private placement of 500,000 shares to Sanofi. The company aims to develop CRISPR-based genetic medicines.
Read more →-SCTX
Jul 24, 2026Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
Scribe Therapeutics has announced the pricing of its upsized initial public offering, offering 8,580,000 shares at $15.00 each, aiming for gross proceeds of $128.7 million. The shares will begin trading on Nasdaq under the symbol 'SCTX' on July 24, 2026. Additionally, a concurrent private placement of 500,000 shares to Sanofi is also set to close on July 27, 2026.
Read more →Competitive Position
How SCTX ranks across every disease it competes inCompetitive Position is a premium feature
See how SCTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial